<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> is a multi-step process, first requiring virus binding to the host cell, followed by fusion of the <z:mp ids='MP_0001799'>viral</z:mp> envelope with the host cell plasma membrane </plain></SENT>
<SENT sid="1" pm="."><plain>Efficient EBV entry into B cells requires, at the minimum, the interaction of the EBV-encoded <z:chebi fb="0" ids="17089">glycoproteins</z:chebi> gp350 with cellular CD21 and gp42 with MHC class II proteins </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, use of the cholesterol-binding drugs <z:chebi fb="36" ids="29309">methyl</z:chebi>-beta-cyclodextrin and nystatin efficiently inhibited <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> of target Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> B-cell lines, indicating an important role for cholesterol and suggesting the involvement of <z:chebi fb="23" ids="18059">lipid</z:chebi> rafts in <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
</text></document>